Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4887369 | 1.00 | CHRM1 (0.51) | CHRM1ENPP2ALDH1A1POLBMEN1 | |
| SCHEMBL4888549 | 0.89 | CHRM1 (0.67) | CHRM1ENPP2ALDH1A1MAPTHTT | |
| SCHEMBL3466012 | 0.82 | CHRM1 (0.52) | CHRM1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL4889456 | 0.81 | CHRM1 (0.50) | CHRM1ENPP2ALDH1A1POLBMEN1 | |
| SCHEMBL3466812 | 0.80 | CHRM1 (0.50) | CHRM1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL3465898 | 0.80 | CHRM1 (0.50) | CHRM1ALDH1A1MEN1KMT2AMAPT | |
| SCHEMBL13648936 | 0.80 | F10 (0.45) | CHRM1LMNA | |
| SCHEMBL3202706 | 0.78 | CHRM1 (0.58) | CHRM1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3202010 | 0.78 | CHRM1 (0.58) | CHRM1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL3202397 | 0.78 | MAOB (0.55) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | JIRICEK JAN | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275035-A1 | Nitroimidazole Compounds | NQO2, NQO1, MT-ND2 | CHRM1 1746/4885ENPP2 1233/4885ALDH1A1 927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.